Palbociclib in hormone-receptor-positive advanced breast cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer. METHODS: This phase 3 study involved 521 patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that had relapsed or progressed during prior endocrine therapy. We randomly assigned patients in a 2:1 ratio to receive palbociclib and fulvestrant or placebo and fulvestrant. Premenopausal or perimenopausal women also received goserelin. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival, objective response, rate of clinical benefit, patient-reported outcomes, and safety. A preplanned interim analysis was performed by an independent data and safety monitoring committee after 195 events of disease progression or death had occurred. RESULTS: The median progression-free survival was 9.2 months (95% confidence interval [CI], 7.5 to not estimable) with palbociclib-fulvestrant and 3.8 months (95% CI, 3.5 to 5.5) with placebo-fulvestrant (hazard ratio for disease progression or death, 0.42; 95% CI, 0.32 to 0.56; P<0.001). The most common grade 3 or 4 adverse events in the palbociclib-fulvestrant group were neutropenia (62.0%, vs. 0.6% in the placebo-fulvestrant group), leukopenia (25.2% vs. 0.6%), anemia (2.6% vs. 1.7%), thrombocytopenia (2.3% vs. 0%), and fatigue (2.0% vs. 1.2%). Febrile neutropenia was reported in 0.6% of palbociclib-treated patients and 0.6% of placebo-treated patients. The rate of discontinuation due to adverse events was 2.6% with palbociclib and 1.7% with placebo. CONCLUSIONS: Among patients with hormone-receptor-positive metastatic breast cancer who had progression of disease during prior endocrine therapy, palbociclib combined with fulvestrant resulted in longer progression-free survival than fulvestrant alone. (Funded by Pfizer; PALOMA3 ClinicalTrials.gov number, NCT01942135.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an interim analysis reported PFS of 9.2 months with palbociclib-fulvestrant and 3.8 months with placebo-fulvestrant (hazard ratio 0.42)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [84]
In the citing paper
“This study enrolled pre- and peri-menopausal patients, with benefit of the combination observed across groups.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [84]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationThe history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412379 · Cited by 726
Cited by
Items 201–300 of 1,000
Targeted Therapies for Brain Metastases from Breast Cancer
Venur, V. A., & Leone, J. P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091543 · Cited by 96
ESR1 alterations and metastasis in estrogen receptor positive breast cancer
Lei, J. T., Gou, X., Şeker, S., & Ellis, M. J. (2019) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2019.12 · Cited by 117
Approaches to modernize the combination drug development paradigm
Day, D., & Siu, L. L. (2016) · Genome Medicine · doi:10.1186/s13073-016-0369-x · Cited by 104
Larionov, A. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00089 · Cited by 102
Xi, J., Oza, A., Thomas, S. N., Ademuyiwa, F. O., Weilbaecher, K. N., Suresh, R., Bose, R., Cherian, M. A., Hernandez-Aya, L. F., Frith, A. E., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7094 · Cited by 95
Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients
Tamura, K., Mukai, H., Naito, Y., Yonemori, K., Kodaira, M., Tanabe, Y., Yamamoto, N., Osera, S., Sasaki, M., Mori, Y., et al. (2016) · Cancer Science · doi:10.1111/cas.12932 · Cited by 92
A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
Guenther, L. M., Dharia, N. V., Ross, L. S., Conway, A. S., Robichaud, A. L., Catlett, J. L., Wechsler, C. S., Frank, E. S., Goodale, A. B., Church, A. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0372 · Cited by 100
Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions
Vijayaraghavan, S., Moulder, S., Keyomarsi, K., & Layman, R. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0541-2 · Cited by 99
Pancholi, S., Ribas, R., Simigdala, N., Schuster, E. F., Nikitorowicz-Buniak, J., Ressa, A., Gao, Q., Leal, M. F., Bhamra, A., Thornhill, A. M., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1284-6 · Cited by 98
Cyclin-Dependent Kinases as Coregulators of Inflammatory Gene Expression
Schmitz, M. L., & Kracht, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.10.004 · Cited by 98
Transcription and Translation Inhibitors in Cancer Treatment
Laham-Karam, N., Pinto, G., Poso, A., & Kokkonen, P. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00276 · Cited by 95
Targeting the androgen receptor in triple-negative breast cancer
Gucalp, A., & Traina, T. A. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.09.004 · Cited by 98
Johnston, S. R. D. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv212 · Cited by 92
Sanchez, G. J., Richmond, P. A., Bunker, E. N., Karman, S. S., Azofeifa, J., Garnett, A. T., Xu, Q., Wheeler, G. E., Toomey, C. M., Zhang, Q., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1225 · Cited by 93
The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma
García-Reyes, B., Kretz, A.-L., Ruff, J.-P., von Karstedt, S., Hillenbrand, A., Knippschild, U., Henne‐Bruns, D., & Lemke, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103219 · Cited by 102
“Phase III Advanced breast cancer [252] In combination with fulvestrant”
BackgroundLin, D. I., Allen, J. M., Hecht, J. L., Killian, J. K., Ngo, N., Edgerly, C. I., Severson, E. A., Ali, S. M., Erlich, R., Ramkissoon, S. H., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0303-z · Cited by 94
Jin, X., Ge, L., Li, D., Shao, Z., Di, G. H., Xu, X., & Jiang, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01210-9 · Cited by 104
c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis
Ji, W., Zhang, W., Wang, X., Shi, Y., Yang, F., Xie, H., Zhou, W., Wang, S., & Guan, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02980-2 · Cited by 94
RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease
Mandigo, A. C., Yuan, W., Xu, K., Gallagher, P., Pang, A., Guan, Y. F., Shafi, A. A., Thangavel, C., Sheehan, B., Bogdan, D., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1114 · Cited by 91
Rugo, H. S., Turner, N. C., Finn, R. S., Joy, A. A., Verma, S., Harbeck, N., Masuda, N., Im, S., Huang, X., Kim, S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.017 · Cited by 92
Self-citationPalbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
Hernandez-Aya, L. F., & Ma, C. X. (2016) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2016.09.017 · Cited by 89
A contemporary review of male breast cancer: current evidence and unanswered questions
Leon-Ferre, R. A., Giridhar, K. V., Hieken, T. J., Mutter, R. W., Couch, F. J., Jiménez, R. E., Hawse, J. R., Boughey, J. C., & Ruddy, K. J. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9761-x · Cited by 96
Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment
Zheng, G., & Leone, J. P. (2022) · Journal of Oncology · doi:10.1155/2022/1734049 · Cited by 89
Medicinal chemistry perspective of pyrido[2,3- d ]pyrimidines as anticancer agents
Kumar, A., Bhagat, K. K., Singh, A. K., Singh, H., Angre, T. D., Verma, A., Khalilullah, H., Jaremko, M., Emwas, A.-H. M., & Kumar, P. (2023) · RSC Advances · doi:10.1039/d3ra00056g · Cited by 97
Alves, C. L., Ehmsen, S., Terp, M. G., Portman, N., Tuttolomondo, M., Gammelgaard, O. L., Hundebøl, M. F., Kaminska, K. K., Johansen, L. E., Bak, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25422-9 · Cited by 97
Selli, Ç., Dixon, J. M., & Sims, A. H. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0779-0 · Cited by 98
Vidula, N., & Rugo, H. S. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.07.005 · Cited by 96
Breast Cancer in Women Older Than 80 Years
Shachar, S. S., Hurria, A., & Muss, H. B. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.010207 · Cited by 91
Molecular Oncology of Breast Cancer
Joshi, H. N., & Press, M. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35955-9.00022-2 · Cited by 97
Spring, L. M., Bardia, A., & Modi, S. (2016) · PubMed · Cited by 105
Breast cancer treatment-induced cardiotoxicity
Martel, S., Maurer, C., Lambertini, M., Ponde, N. F., & de Azambuja, E. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1351541 · Cited by 89
Adams, M. N., Burgess, J. T., He, Y., Gately, K. A., Snell, C. E., Zhang, S., Hooper, J. D., Richard, D. J., & O'Byrne, K. J. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.018 · Cited by 88
Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response
Guarducci, C., Bonechi, M., Boccalini, G., Benelli, M., Risi, E., Leo, A. D., Malorni, L., & Migliaccio, I. (2017) · Breast Care · doi:10.1159/000484167 · Cited by 91
Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives
Watase, C., Shiino, S., Shimoi, T., Noguchi, E., Kaneda, T., Yamamoto, Y., Yonemori, K., Takayama, S., & Suto, A. (2021) · Cancers · doi:10.3390/cancers13051078 · Cited by 88
Mistry, R. A., May, J. R., Suri, G., Young, K. C., Brixner, D. I., Oderda, G. M., BISKUPIAK, J. E., Tang, D. H., Bhattacharyya, S., Mishra, D., et al. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.6.514 · Cited by 95
Long, F., He, Y., Fu, H., Li, Y., Bao, X., Wang, Q., Wang, Y., Xie, C., & Lou, L. (2019) · Cancer Science · doi:10.1111/cas.13957 · Cited by 87
The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing
Hylebos, M., Camp, G. V., van Meerbeeck, J. P., & de Beeck, K. O. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.020 · Cited by 91
Role of Apelin/APJ axis in cancer development and progression
Masoumi, J., Jafarzadeh, A., Khorramdelazad, H., Abbasloui, M., Abdolalizadeh, J., & Jamali, N. (2020) · Advances in Medical Sciences · doi:10.1016/j.advms.2020.02.002 · Cited by 89
Li, J., Huo, X., Zhao, F., Ren, D., Ahmad, R., Yuan, X., Du, F., & Zhao, J. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.20312 · Cited by 97
Zhou, Y., Jin, X., Ma, J., Ding, D., Huang, Z., Sheng, H., Yan, Y., Pan, Y., Wei, T., Wang, L., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2828 · Cited by 89
Dickler, M. N., Saura, C., Richards, D., Krop, I. E., Cervantes, A. M. R., Bedard, P. L., Patel, M. R., Pusztai, L., Oliveira, M., Cardenas, A. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0613 · Cited by 86
Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma
Zhou, Y., Shen, J. K., Yu, Z., Hornicek, F. J., Kan, Q., & Duan, Z. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.02.004 · Cited by 87
CDK4 is an essential insulin effector in adipocytes
Lagarrigue, S., Lopez-Mejia, I. C., Denechaud, P.-D., Escoté, X., Castillo-Armengol, J., Jimenez, V., Chavey, C., Giralt, A., Lai, Q., Zhang, L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81480 · Cited by 76
RetractedThe emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer
Zhou, Y., Shen, J. K., Hornicek, F. J., Kan, Q., & Duan, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.8519 · Cited by 90
Ikeda, S., Tsigelny, I. F., Skjevik, Å. A., Kono, Y., Mendler, M. H., Kuo, A., Sicklick, J. K., Heestand, G. M., Banks, K. C., Talasaz, A. H., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0479 · Cited by 84
Girardi, D. M., Silva, A. C. B., Rêgo, J. F. M., Coudry, R. A., & Riechelmann, R. P. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.04.002 · Cited by 84
Xu, B., Hu, X., Li, W., Sun, T., Shen, K., Wang, S., Cheng, Y., Zhang, Q., Cui, S., Tong, Z., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.08.012 · Cited by 88
Azoulay, L. (2022) · The Oncologist · doi:10.1093/oncolo/oyac114 · Cited by 79
CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
Dall’Acqua, A., Sonego, M., Pellizzari, I., Pellarin, I., Canzonieri, V., D’Andrea, S., Benevol, S., Sorio, R., Giorda, G., Califano, D., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607012 · Cited by 82
Translational and clinical implications of the genetic landscape of prostate cancer
Spratt, D. E., Zumsteg, Z. S., Feng, F. Y.-C., & Tomlins, S. A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.76 · Cited by 86
CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities
Lynce, F. C., Shajahan‐Haq, A. N., & Swain, S. M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.008 · Cited by 85
“In PALOMA-3 study, a phase III randomized (2:1) double blind study, 521 patients with HR-positive, HER2-negative breast cancer that relapsed or progressed on previous endocrine therapy were assigned to fulvestrant with palbociclib or placebo (Turner et al., 2015).”
Rajput, S., Khera, N., Guo, Z., Hoog, J., Li, S., & Ma, C. X. (2016) · Oncotarget · doi:10.18632/oncotarget.10870 · Cited by 81
Ballinger, T. J., Meier, J. B., & Jansen, V. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00308 · Cited by 82
David, S., Tan, J., Savas, P. S., Bressel, M., Kelly, D., Foroudi, F., Loi, S., & Siva, S. (2019) · The Breast · doi:10.1016/j.breast.2019.10.016 · Cited by 82
Self-citationLaderian, B., & Fojo, T. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.03.006 · Cited by 77
Taylor‐Stokes, G., Mitra, D., Waller, J., Gibson, K., Milligan, G., & Iyer, S. S. (2018) · The Breast · doi:10.1016/j.breast.2018.10.009 · Cited by 80
Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials
Panagiotou, Ε., Gomatou, G., Trontzas, I. P., Syrigos, N. K., & Kotteas, E. A. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02688-5 · Cited by 81
U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review
Arora, S., Narayan, P., Osgood, C. L., Wedam, S. B., Prowell, T. M., Gao, J. J., Shah, M., Krol, D., Wahby, S., Royce, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2600 · Cited by 82
Al-Warhi, T. I., Sallam, A.-A. M., Hemeda, L. R., Hassab, M. A. E., Aljaeed, N., Alotaibi, O. J., Doghish, A. S., Noshy, M., Eldehna, W. M., & Ibrahim, M. H. (2022) · Pharmaceuticals · doi:10.3390/ph15101262 · Cited by 80
Fulvestrant in advanced breast cancer: evidence to date and place in therapy
Boér, K. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017711097 · Cited by 83
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
D'souza, A., SPICER, D. V., & Lu, J. M. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0620-6 · Cited by 78
Haricharan, S., Punturi, N. B., Singh, P., Holloway, K. R., Anurag, M., Schmelz, J. L., Schmidt, C., Lei, J. T., Suman, V. J., Hunt, K. K., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1179 · Cited by 78
Cristofanilli, M., DeMichele, A., Giorgetti, C., Turner, N. C., Slamon, D. J., Im, S.-A., Masuda, N., Verma, S., Loi, S., Colleoni, M., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.08.011 · Cited by 75
Self-citationMukai, H., Shimizu, C., Masuda, N., Ohtani, S., Ohno, S., Takahashi, M., Yamamoto, Y., Nishimura, R., Sato, N., Ohsumi, S., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1353-9 · Cited by 81
Self-citationJérusalem, G., Mariani, G., Ciruelos, E., Martín, M., Tjan‐Heijnen, V. C. G., Neven, P., Gavila, J. G., Michelotti, A., Montemurro, F., Generali, D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw249 · Cited by 76
“Two different targeted agents, everolimus [a mammalian target of rapamycin (mTOR) inhibitor] and palbociclib (a cyclin-dependent kinase 4/6 inhibitor), have each shown efficacy in this patient population [7, 8].”
BackgroundBagegni, N. A., Thomas, S. N., Liu, N., Luo, J. R., Hoog, J., Northfelt, D., Goetz, M. P., Forero, A., Bergqvist, M., Karén, J., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0913-7 · Cited by 78
Shee, K., Yang, W., Hinds, J. W., Hampsch, R. A., Varn, F. S., Traphagen, N. A., Patel, K., Cheng, C., Jenkins, N. P., Kettenbach, A. N., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171818 · Cited by 73
“CDK4/6 inhibition with palbociclib, which is approved for the treatment of advanced ER+ breast cancer in combination with anti-estrogens (Turner et al., 2015; Finn et al., 2016), abrogated FGF2-mediated rescue from anti-estrogens, PI3Ki, and mTORC1i (Figs.”
BackgroundContostavlos, D. L. (1971) · PubMed · Cited by 75
Targeting CDK4/6 in breast cancer
Shanabag, A., Armand, J., Son, E., & Yang, H. W. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01395-3 · Cited by 80
Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician
Lheureux, S., Denoyelle, C., Ohashi, P. S., Bono, J. S. D., & Mottaghy, F. M. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3695-3 · Cited by 81
Xiao, T., Li, W., Wang, X., Xu, H., Yang, J., Wu, Q., Huang, Y., Geradts, J., Jiang, P., Fei, T., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1722617115 · Cited by 75
Hanaford, A. R., Archer, T. C., Price, A. C., Kahlert, U. D., Maciaczyk, J., Nikkhah, G., Kim, J. W., Ehrenberger, T., Clemons, P. A., Dančík, V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3011 · Cited by 80
Silvestri, M., Cristaudo, A., Morrone, A., Messina, C., Bennardo, L., Nisticò, S. P., Mariano, M., & Cameli, N. (2021) · Drug Safety · doi:10.1007/s40264-021-01071-1 · Cited by 73
CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure
Garrido-Castro, A. C., & Goel, S. (2017) · Current Breast Cancer Reports · doi:10.1007/s12609-017-0232-0 · Cited by 69
Pascual, J., Lim, J. S. J., Macpherson, I. R., Armstrong, A. C., Ring, A. E., Okines, A. F. C., Cutts, R. J., Herrera-Abreu, M. T., García-Murillas, I., Pearson, A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0553 · Cited by 79
Self-citationTreatment of drug-induced immune thrombocytopenias
Marini, I., Uzun, G., Jamal, K., & Bakchoul, T. (2022) · Haematologica · doi:10.3324/haematol.2021.279484 · Cited by 76
Lu, J. M. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0194-5 · Cited by 73
Park, J. K., Byun, J., Park, J. A., Kim, Y.-Y., Lee, Y. J., Oh, J. I., Jang, S. Y., Kim, Y., Song, Y. W., Son, J., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0988-z · Cited by 71
Bardia, A., Aftimos, P. G., Bihani, T., Anderson-Villaluz, A. T., Jung, J., Conlan, M. G., & Kaklamani, V. (2019) · Future Oncology · doi:10.2217/fon-2019-0370 · Cited by 73
Palbociclib-induced autophagy and senescence in gastric cancer cells
Valenzuela, C. A., Vargas, L., Martinez, V., Bravo, S., & Brown, N. E. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.09.031 · Cited by 67
Li, B., Li, A., You, Z., Xu, J., & Zhu, S. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03031-6 · Cited by 69
Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
Scheidemann, E. R., & Shajahan‐Haq, A. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212292 · Cited by 74
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
Asciolla, J. J., Wu, X., Adamopoulos, C., Gavathiotis, E., & Poulikakos, P. I. (2025) · Nature Cancer · doi:10.1038/s43018-024-00893-z · Cited by 73
Alves, C. L., Eliáš, D., Lyng, M., Bak, M., Kirkegaard, T., Lykkesfeldt, A. E., & Ditzel, H. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1984 · Cited by 74
Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma
Mariño‐Enríquez, A., & Bovée, J. V. M. G. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.04.009 · Cited by 73
Precision medicine in breast cancer: reality or utopia?
Bettaïeb, A., Paul, C., Plenchette, S., Shan, J., Chouchane, L., & Ghiringhelli, F. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1239-z · Cited by 79
Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began
Meisel, J. L., Venur, V. A., Gnant, M., & Carey, L. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201037 · Cited by 78
Combinatorial drug therapy in cancer - New insights
Bhatia, K. S., Bhumika, & Das, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118134 · Cited by 75
Niu, X., Ma, J., Li, J., Gu, Y., Yin, L., Wang, Y., Zhou, X., Wang, J., Ji, H., & Zhang, Q. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03781-x · Cited by 70
O'Sullivan, C. C., Clarke, R. C., Goetz, M. P., & Robertson, J. F. R. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2000 · Cited by 75
Liu, C., Lau, K.-Y., Hsu, C., Chen, J.-L., Lee, C.-H., Huang, T., Chen, Y., Huang, C.-T., Lin, P., & Tseng, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189007 · Cited by 71
Baslan, T., Kendall, J., Volyanskyy, K. Y., McNamara, K. L., Cox, H., D'Italia, S., Ambrosio, F. J., Riggs, M. G., Rodgers, L., Leotta, A., et al. (2020) · eLife · doi:10.7554/elife.51480 · Cited by 70
Roberto, M., Astone, A., Botticelli, A., Carbognin, L., Cassano, A., D’Auria, G., Fabbri, A., Fabi, A., Gamucci, T., Krasniqi, E., et al. (2021) · Cancers · doi:10.3390/cancers13020332 · Cited by 72
Luo, L., Yang, P., Mastoraki, S., Rao, X., Wang, Y., Kettner, N. M., Raghavendra, A. S., Tripathy, D., Damodaran, S., Hunt, K. K., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02226-9 · Cited by 70
Bellet, M., Ahmad, F., Villanueva-Vázquez, R., Valdivia, C., Palomino-Doza, J., Ruiz, A. I., González, X., Adrover, E., Azaro, A., Valls-Margarit, M., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919833867 · Cited by 68
Signal Transduction in Diffuse Intrinsic Pontine Glioma
Duchatel, R. J., Jackson, E. R., Alvaro, F., Nixon, B., Hondermarck, H., & Dun, M. D. (2019) · PROTEOMICS · doi:10.1002/pmic.201800479 · Cited by 72
CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane‐induced alopecia
Purba, T. S., Ng’andu, K., Brunken, L., Smart, E., Mitchell, E., Hassan, N. M. K. N., O'Brien, A., Mellor, C. E. L., Jackson, J., Shahmalak, A., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201911031 · Cited by 70
Lin, D. I., Hemmerich, A. C., Edgerly, C. I., Duncan, D. L., Severson, E. A., Huang, R. S. P., Ramkissoon, S. H., Connor, Y., Shea, M., Hecht, J. L., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.02.024 · Cited by 67
Novel Molecular Markers for Breast Cancer
Inoue, K., & Fry, E. A. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s38394 · Cited by 70
Finn, R. S., Rugo, H. S., Gelmon, K. A., Cristofanilli, M., Colleoni, M. A., Loi, S., Schnell, P., Lu, D. R., Theall, K. P., Mori, A., et al. (2021) · The Oncologist · doi:10.1002/onco.13684 · Cited by 68
Self-citation
Metadata
- Authors
- Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., Giorgetti, C., Randolph, S., Koehler, M., & Cristofanilli, M.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- National Cancer Center (KR)
- Institut Gustave Roussy (FR)
- The University of Melbourne (AU)
- Aichi Cancer Center Hospital (JP)
- Ludwig-Maximilians-Universität München (DE)
- German Breast Group (DE)
- Pfizer (United States) (US)
- Thomas Jefferson University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-16
- Volume
- 373
- Issue
- 3
- Pages
- 209-219
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1464936406
- Cited by
- 1,590
- References
- 26
- Citations by year
- 2026: 67 · 2025: 142 · 2024: 117 · 2023: 109 · 2022: 127 · 2021: 142 · 2020: 172 · 2019: 123 · 2018: 169 · 2017: 193 · 2016: 179 · 2015: 49
- FWCI
- 154.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- The Medicine Forum (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, hormone receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, fulvestrant, progression-free survival, endocrine therapy resistance, neutropenia, febrile neutropenia, goserelin, metastatic breast cancer, G1/S transition, adverse events, overall survival
- MeSH terms
- Fulvestrant, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Estradiol, Female, Humans, Middle Aged, Piperazines, Pyridines, Receptors, Estrogen, Receptors, Progesterone, Biomarkers, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.